Format

Send to

Choose Destination
Mol Pharm. 2016 Sep 6;13(9):3279-91. doi: 10.1021/acs.molpharmaceut.6b00568. Epub 2016 Aug 8.

Zinc-Stabilized Chitosan-Chondroitin Sulfate Nanocomplexes for HIV-1 Infection Inhibition Application.

Author information

1
Ingénierie des Matériaux Polymères, UMR CNRS 5223, Université Claude Bernard Lyon 1 , 15 Bd. André Latarjet, 69622 Villeurbanne Cedex, France.
2
Institut de Biologie et Chimie des Protéines UMR 5305, CNRS/Université de Lyon , 69367 Lyon Cedex 07, France.
3
ADJUVATIS-7 , passage du Vercors, 69367 Lyon Cedex 07, France.
4
B-Cell Design , 98 Rue Charles Legendre, 87000 Limoges, France.
5
Groupe Immunité des Muqueuses et Agents Pathogènes, INSERM Centre d'Investigation Clinique en Vaccinologie 1408, Université de Lyon , 15 rue Ambroise Paré, 42023 Saint-Etienne Cedex 2, France.

Abstract

Polyelectrolyte complexes (PECs) constituted of chitosan and chondroitin sulfate (ChonS) were formed by the one-shot addition of default amounts of polyanion to an excess of polycation. Key variables of the formulation process (e.g., degree of depolymerization, charge mixing ratio, the concentration, and pH of polyelectrolyte solutions) were optimized based on the PECs sizes and polydispersities. The PECs maintained their colloidal stability at physiological salt concentration and pH thanks to the complexation of polyelectrolytes with zinc(II) ion during the nanoPECs formation process. The PECs were capable of encapsulating an antiretroviral drug tenofovir (TF) with a minimal alteration on the colloidal stability of the dispersion. Moreover, the particle interfaces could efficiently be functionalized with anti-OVA or anti-α4β7 antibodies with conservation of the antibody biorecognition properties over 1 week of storage in PBS at 4 °C. In vitro cytotoxicity studies showed that zinc(II) stabilized chitosan-ChonS nanoPECs were noncytotoxic to human peripheral blood mononuclear cells (PBMCs), and in vitro antiviral activity test demonstrated that nanoparticles formulations led to a dose-dependent reduction of HIV-1 infection. Using nanoparticles as a drug carrier system decreases the IC50 (50% inhibitory concentration) from an aqueous TF of 4.35 μmol·L(-1) to 1.95 μmol·L(-1). Significantly, zinc ions in this system also exhibited a synergistic effect in the antiviral potency. These data suggest that chitosan-ChonS nanoPECs can be promising drug delivery system to improve the antiviral potency of drugs to the viral reservoirs for the treatment of HIV infection.

KEYWORDS:

HIV infection inhibition; chitosan; chondroitin sulfate; polyelectrolyte complexes; stabilization

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center